FOLH1 and prostate cancer: The combination of 68 Ga-PSMA-11 PET/CT and mpMRI (mpMRI + PET/CT) is able to improve the detection of clinically significant prostate cancer (csPCa), which means that more accurate initial diagnosis requires more sophisticated techniques [5].